Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23104618 | 1.00 | MGLL (0.32) | MGLLIRAK4MAP4K1 | |
| SCHEMBL23104199 | 1.00 | MGLL (0.32) | MGLLIRAK4MAP4K1 | |
| SCHEMBL23750958 | 0.83 | — | — | |
| SCHEMBL23107315 | 0.81 | IRAK4 (0.34) | MGLLIRAK4MAP4K1 | |
| SCHEMBL31710948 | 0.81 | PDE4A (0.33) | — | |
| SCHEMBL23541778 | 0.81 | IRAK4 (0.34) | MGLLIRAK4MAP4K1 | |
| SCHEMBL24375510 | 0.81 | IRAK4 (0.34) | MGLLIRAK4MAP4K1 | |
| SCHEMBL24871972 | 0.80 | IRAK4 (0.35) | MGLLIRAK4MAP4K1 | |
| SCHEMBL24375899 | 0.79 | IRAK4 (0.34) | MGLLIRAK4MAP4K1 | |
| SCHEMBL20938118 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617802-B2 | Sulfonimidamide compounds as NLRP3 modulators | GENENTECH, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-11718631-B2 | Sulphonamides and compositions thereof for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2023-08-08 | — | — | US | disclosed |
| US-11702428-B2 | Chemical compounds as inhibitors of interleukin-1 activity | GENENTECH, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230159555-A1 | SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS | GENENTECH, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159555-A1 | SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS | GENENTECH, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159555-A1 | SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS | GENENTECH, INC. (US) | 2023-05-25 | — | — | US | disclosed |
| CN-115461120-A | Sulfonylimide compounds as NLRP3 modulators | 豪夫迈·罗氏有限公司 | 2022-12-09 | — | — | CN | disclosed |
| WO-2021150574-A1 | SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS | GENENTECH, INC. (US) | 2021-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159555-A1 | SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS | NLRP3, NLRP1, PYCARD | MGLL 4115/4885IRAK4 14/4885MAP4K1 1866/4885 |
| US-12617802-B2 | Sulfonimidamide compounds as NLRP3 modulators | NLRP3, NLRP1, PYCARD | MGLL 4757/4885IRAK4 17/4885MAP4K1 2692/4885 |
| US-11718631-B2 | Sulphonamides and compositions thereof for treating conditions associated with NLRP activity | NLRP1, NLRP3, NOD1 | MGLL 3011/4885IRAK4 12/4885MAP4K1 2353/4885 |
| US-11702428-B2 | Chemical compounds as inhibitors of interleukin-1 activity | IL1B, IL1A, IL18 | MGLL 2958/4885IRAK4 13/4885MAP4K1 1925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.